Citations (30)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (6)
Hirohito Shimizu, Hisanori Kobayashi, Masayoshi Kanbori & Yutaka Ishii. (2021) Effectiveness of golimumab in rheumatoid arthritis patients with inadequate response to first-line biologic therapy: Results from a Japanese post-marketing surveillance study. Modern Rheumatology 31:3, pages 556-565.
Read now
Read now
C. Chen, M. E. Borrego, M. H. Roberts & D. W. Raisch. (2019) Comparison of post-marketing surveillance approaches regarding infections related to tumor necrosis factor inhibitors (TNFi’s) used in treatment of autoimmune diseases. Expert Opinion on Drug Safety 18:8, pages 733-744.
Read now
Read now
K Chatzidionysiou. (2016) Optimizing biological treatments for rheumatoid arthritis. Scandinavian Journal of Rheumatology 45:sup128, pages 64-75.
Read now
Read now
Roy Fleischmann, John A. Goldman, Marjatta Leirisalo-Repo, Ellen Zanetakis, Hisham El-Kadi, Herbert Kellner, Rebecca Bolce, Raphael DeHoratius, Jim Wang & Dennis Decktor. (2014) Infliximab efficacy in rheumatoid arthritis after an inadequate response to etanercept or adalimumab: results of a target-driven active switch study. Current Medical Research and Opinion 30:11, pages 2139-2149.
Read now
Read now
Homa Timlin & Clifton O Bingham$suffix/text()$suffix/text(). (2014) Efficacy and safety implications of molecular constructs of biological agents for rheumatoid arthritis. Expert Opinion on Biological Therapy 14:7, pages 893-904.
Read now
Read now
P Neregård, A Krishnamurthy, S Revu, M Engström, E af Klint & AI Catrina. (2014) Etanercept decreases synovial expression of tumour necrosis factor-α and lymphotoxin-α in rheumatoid arthritis. Scandinavian Journal of Rheumatology 43:2, pages 85-90.
Read now
Read now
Articles from other publishers (24)
Daniela Siegmund & Harald Wajant. (2023) TNF and TNF receptors as therapeutic targets for rheumatic diseases and beyond. Nature Reviews Rheumatology.
Crossref
Crossref
Charlotte LM Krieckaert, Astrid van Tubergen, Johanna Elin Gehin, Borja Hernández-Breijo, Guillaume Le Mélédo, Alejandro Balsa, Peter Böhm, Sasa Cucnik, Ori Elkayam, Guro L Goll, Femke Hooijberg, Meghna Jani, Patrick DW Kiely, Neil McCarthy, Denis Mulleman, Victoria Navarro-Compán, Katherine Payne, Martin E Perry, Chamaida Plasencia-Rodriguez, Simon R Stones, Silje Watterdal Syversen, Annick de Vries, Katherine M Ward, Gertjan Wolbink & John D Isaacs. (2023) EULAR points to consider for therapeutic drug monitoring of biopharmaceuticals in inflammatory rheumatic and musculoskeletal diseases. Annals of the Rheumatic Diseases 82:1, pages 65-73.
Crossref
Crossref
Johanna Elin Gehin, Guro Løvik Goll, Marthe Kirkesæther Brun, Meghna Jani, Nils Bolstad & Silje Watterdal Syversen. (2022) Assessing Immunogenicity of Biologic Drugs in Inflammatory Joint Diseases: Progress Towards Personalized Medicine. BioDrugs 36:6, pages 731-748.
Crossref
Crossref
Xuefeng Xu, Xiaohui Liu, Wenjie Zheng, Jihong Xiao, Xiaozhong Li, Ling Wu, Lixia Zou, Qian Ouyang, Yaoyao Shangguan, Kezhao Lin, Xiaomei Dai, Yuanling Chen, Yiping Xu, Jianqiang Wu & Meiping Lu. (2022) Efficacy and safety of etanercept biosimilar rhTNFR-Fc in Chinese patients with juvenile idiopathic arthritis: An open-label multicenter observational study. Frontiers in Pediatrics 10.
Crossref
Crossref
Charlotte Krieckaert, Borja Hernández-Breijo, Johanna Elin Gehin, Guillaume le Mélédo, Alejandro Balsa, Meghna Jani, Denis Mulleman, Victoria Navarro-Compan, Gertjan Wolbink, John D Isaacs & Astrid van Tubergen. (2022) Therapeutic drug monitoring of biopharmaceuticals in inflammatory rheumatic and musculoskeletal disease: a systematic literature review informing EULAR points to consider. RMD Open 8:2, pages e002216.
Crossref
Crossref
Alberto Migliore, Giuseppe Pompilio, Davide Integlia, Joe Zhuo & Evo Alemao. (2021)
Cycling of tumor necrosis factor inhibitors
versus
switching to different mechanism of action therapy in rheumatoid arthritis patients with inadequate response to tumor necrosis factor inhibitors: a Bayesian network meta-analysis
. Therapeutic Advances in Musculoskeletal Disease 13, pages 1759720X2110026.
Crossref
Crossref
Edward C. Keystone, Emmanouil Rampakakis, Mohammad Movahedi, Angela Cesta, Melissa Stutz, John S. Sampalis, Francois Nantel, Karina Maslova & Claire Bombardier. (2020) Toward Defining Primary and Secondary Nonresponse in Rheumatoid Arthritis Patients Treated with Anti-TNF: Results from the BioTRAC and OBRI Registries. The Journal of Rheumatology 47:4, pages 510-517.
Crossref
Crossref
Tomohiro Hirose, Yuri Fukuma, Ayumu Takeshita & Keiichiro Nishida. (2018) The role of lymphotoxin-α in rheumatoid arthritis. Inflammation Research 67:6, pages 495-501.
Crossref
Crossref
Gablu Kilcher, Noemi Hummel, Eva M Didden, Matthias Egger & Stephan Reichenbach. (2018) Rheumatoid arthritis patients treated in trial and real world settings: comparison of randomized trials with registries. Rheumatology 57:2, pages 354-369.
Crossref
Crossref
Louis Bessette, Majed Khraishi, Alan J. Kivitz, Arunan Kaliyaperumal, Rama Grantab, Melanie Poulin-Costello, Maya Isaila & David Collier. (2017) Single-Arm Study of Etanercept in Adult Patients with Moderate to Severe Rheumatoid Arthritis Who Failed Adalimumab Treatment. Rheumatology and Therapy 4:2, pages 391-404.
Crossref
Crossref
Susan J. Bartlett, Skye P. Barbic, Vivian P. Bykerk, Ernest H. Choy, Rieke Alten, Robin Christensen, Alfons den Broeder, Bruno Fautrel, Daniel E. Furst, Francis Guillemin, Sarah Hewlett, Amye L. Leong, Anne Lyddiatt, Lyn March, Pamela Montie, Christoph Pohl, Marieke Scholte Voshaar, Thasia G. Woodworth & Clifton O. BinghamIIIIII. (2017) Content and Construct Validity, Reliability, and Responsiveness of the Rheumatoid Arthritis Flare Questionnaire: OMERACT 2016 Workshop Report. The Journal of Rheumatology 44:10, pages 1536-1543.
Crossref
Crossref
Alvin F. Wells, Jeffrey R. Curtis, Keith A. Betts, Kevin Douglas, Ella Xiaoyan Du & Arijit Ganguli. (2017) Systematic Literature Review and Meta-analysis of Tumor Necrosis Factor–Alpha Experienced Rheumatoid Arthritis. Clinical Therapeutics 39:8, pages 1680-1694.e2.
Crossref
Crossref
Katerina Chatzidionysiou, Johan Askling, Jonas Eriksson, Lars Erik Kristensen & Ronald van Vollenhoven. (2015) Effectiveness of TNF inhibitor switch in RA: results from the national Swedish register. Annals of the Rheumatic Diseases 74:5, pages 890-896.
Crossref
Crossref
D. E. Furst, S. A. Shaikh, M. Greenwald, B. Bennett, O. Davies, K. Luijtens, F. Staelens, W. Koetse & P. Bertin. (2015) Two Dosing Regimens of Certolizumab Pegol in Patients With Active Rheumatoid Arthritis. Arthritis Care & Research 67:2, pages 151-160.
Crossref
Crossref
Becky Pennington & Sarah Davis. (2014) Mapping from the Health Assessment Questionnaire to the EQ-5D: The Impact of Different Algorithms on Cost-Effectiveness Results. Value in Health 17:8, pages 762-771.
Crossref
Crossref
Onur Boyman, Denis Comte & François Spertini. (2014) Adverse reactions to biologic agents and their medical management. Nature Reviews Rheumatology 10:10, pages 612-627.
Crossref
Crossref
Frank R. Brennan. 2014. Handbook of Therapeutic Antibodies. Handbook of Therapeutic Antibodies
969
1078
.
C.-Y. Chen & C.-Y. Tsai. (2013) From endocrine to rheumatism: do gut hormones play roles in rheumatoid arthritis?. Rheumatology 53:2, pages 205-212.
Crossref
Crossref
Sylwia Bujkiewicz, John R. Thompson, Alex J. Sutton, Nicola J. Cooper, Mark J. Harrison, Deborah P.M. Symmons & Keith R. Abrams. (2014) Use of Bayesian Multivariate Meta-Analysis to Estimate the HAQ for Mapping Onto the EQ-5D Questionnaire in Rheumatoid Arthritis. Value in Health 17:1, pages 109-115.
Crossref
Crossref
Takao Koike, Masayoshi Harigai, Shigeko Inokuma, Naoki Ishiguro, Junnosuke Ryu, Tsutomu Takeuchi, Yoshiya Tanaka, Hisashi Yamanaka, Koichi Fujii, Takunari Yoshinaga, Bruce Freundlich & Michio Suzukawa. (2011) Safety and effectiveness responses to etanercept for rheumatoid arthritis in Japan: a sub-analysis of a post-marketing surveillance study focusing on the duration of rheumatoid arthritis. Rheumatology International 32:6, pages 1511-1519.
Crossref
Crossref
K. Chatzidionysiou & R. F. van Vollenhoven. (2011) When to initiate and discontinue biologic treatments for rheumatoid arthritis?. Journal of Internal Medicine 269:6, pages 614-625.
Crossref
Crossref
Regina Rendas-Baum, Gene V Wallenstein, Tamas Koncz, Mark Kosinski, Min Yang, John Bradley & Samuel H Zwillich. (2011) Evaluating the efficacy of sequential biologic therapies for rheumatoid arthritis patients with an inadequate response to tumor necrosis factor-α inhibitors. Arthritis Research & Therapy 13:1.
Crossref
Crossref
S. Lloyd, S. Bujkiewicz, A. J. Wailoo, A. J. Sutton & D. Scott. (2010) The effectiveness of anti-TNF- therapies when used sequentially in rheumatoid arthritis patients: a systematic review and meta-analysis. Rheumatology 49:12, pages 2313-2321.
Crossref
Crossref
. (2009) Current awareness: Pharmacoepidemiology and drug safety. Pharmacoepidemiology and Drug Safety 18:12.
Crossref
Crossref